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Diﬀerent natural clay minerals, including halloysite, montmorillonite and kaolinite, have been proven to be
eﬃcient drug carriers providing for high and long lasting drug concentrations owing to their adsorption
capacity and ion exchange property. Synthetic clays, however, are advantageous over the natural clay
minerals in terms of purity of composition and controllable cation exchange capacity, factors that
contribute to improve reproducibility of the host system. Here we studied a synthetic smectite clay as
a candidate for high adsorption and controlled release rate. Via X-ray powder diﬀraction we veriﬁed that,
under acidic conditions, the antibiotic ciproﬂoxacin was successfully incorporated in the synthetic clay
ﬂuorohectorite, while via UV-VIS spectroscopy we showed that the degree of the drug incorporation is
at least 25% higher than for other systems reported in the literature. Furthermore, temperature
dependent release studies allowed us to show that the release process is thermally activated and
diﬀusion-controlled. Finally, via bacterial and toxicological tests, we demonstrated that the eﬀectiveness
and toxicity of pure ciproﬂoxacin is unaﬀected in the clay–drug complex.Introduction
Controlled drug release systems show several advantages over
conventional dosage forms. Besides manipulating the release
rate, drug encapsulation oﬀers, among others, protection
against drug hydrolysis, chemical degradation as well as
decrease in drug toxicity.1–5 Over the last decade, diﬀerent
porous materials have been used as hosts for drug encapsula-
tion,3–12 including natural and synthetic smectite clays.2,13–17
Important factors that facilitate drug intercalation in clay
systems are: (i) clay particles undergo crystalline swelling,18–20
(ii) the tunability of their net negative structural charge by
isomorphic substitution of the interlayer cation21 and (iii) their
non-toxicity for transdermal application and oral administra-
tion.11,14–17 Among clay minerals, montmorillonite has been the
most commonly studied for drug delivery applications.14,15,22,23
Although, compared with natural smectites, synthetic clayssity of Science and Technology (NTNU),
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hemistry 2017show a number of advantages that contribute to improved
reproducibility of the host system, such as purity of composi-
tion, controllable cation exchange capacity (CEC) and pore size
distributions, not many studies have been devoted to the study
of drugs encapsulated in synthetic clays.13,24 It is in this context
that the current study focuses on intercalation and release of
the antibiotic ciprooxacin (CIPRO) in the synthetic clay uo-
rohectorite (Fh).
CIPRO, a broad-spectrum antibacterial agent for oral
administration, is used to treat bacterial infections.25–28 Like
other uoroquinolones, CIPRO is zwitterionic exhibiting
a ‘U-shaped’ pH-solubility prole, with a solubility that
increases at high and low pH values. At high pHs CIPRO
acquires a negative charge because of the deprotonation of
the carboxylic group, whereas at low pHs the CIPRO mole-
cules become positively charged because of the protonation of
the amine group. Furthermore, a neutral net charge is
observed around neutral pH.14,28,29 Smectite clays, such as Fh,
consist of deck-of-card-like particles formed by several nega-
tively charged stacked clay unit layers, including intercalated
charge compensating cations. Cations exchange processes are
readily achieved in such systems.30,31 Furthermore previous
work dealing with the encapsulation of CIPRO in LiFh13
motivated us to investigate the possibility of CIPRO adsorp-
tion by intercalation under acidic conditions, where the
CIPRO molecules are positively charged and, in this context,
might “act” as cations.RSC Adv., 2017, 7, 26537–26545 | 26537
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View Article OnlineIn the present study, we use X-ray powder diﬀraction (XRD)
and ultraviolet-visible spectroscopy (UV-VIS) to investigate the
suitability of Li-uorohectorite (LiFh) to incorporate CIPRO,
forming a clay–drug composite, hereaer called CPFh. The
CIPRO adsorption is studied under acidic conditions and its
release by dispersing the clay–drug composite in synthetic
gastric acid (SGA). Based on these results we show that at body
temperature the drug release is thermally activated. In addition,
by means of minimum inhibitory and bactericidal concentra-
tion (MIC and MBC, respectively) as well as cell viability tests we
show that antibacterial activity and toxicity of the clay–drug
complex match that of pure CIPRO.Experimental
Materials
Fluorohectorite has the unit cell chemical formula Cx(Mg(6x)-
Lix)Si8O20F4, with C denoting the exchangeable charge
compensating cation.32 In this study we used LiFh, Li1.2(Mg4.8-
Li1.2)Si8O20F4, purchased from Corning Inc., with Li
+ as cation.
CIPRO, C17H18FN3O3,28 was purchased from Fluka via Sigma-
Aldrich. Both materials were used as received, i.e., without
further purication.Preparation of CIPRO intercalated in Fh: the CPFh composite
analysed with UV-VIS spectroscopy and synchrotron XRD
The molecular weight of the CIPRO molecule is 331.3 g mol1,
and the molecular weight of the LiFh unit cell is 754 g mol1.
Thus, the formation of CPFh requires at least 0.53 g of cipro-
oxacin per 1.00 g of LiFh, assuming that every intercalated Li+
cation in LiFh is exchanged with one CIPROmolecule. Then the
molecular weight of the resulting CPFh unit cell, with chemical
formula (C17H18FN3O3)1.2(Mg4.8Li1.2)Si8O20F4, would be about
1143 g mol1.
Following this line of reasoning, to investigate the amount of
CIPRO needed for complete exchange of Li cations the CPFh
composite was prepared by mixing either 0.25 g of CIPRO with
1.00 g of LiFh (hereaer referred to as batch A) or 1.00 g of
CIPRO with 1.00 g of LiFh (hereaer referred to as batch B) in
200 mL of an aqueous solution adjusted to pH ¼ 2.0 by adding
HCl. At this pH the drug molecules are positively charged, thus
facilitating its cationic exchange with the interlayer Li+. More-
over, to examine the drug intercalation in a more environ-
mentally friendly way, i.e. without the use of chemicals for pH
control, further sorption tests were conducted in pure deionized
aqueous solution (hereaer referred to as batch C).
Considering that temperature might inuence the swelling
properties of the Fh clay particles,32 the solutions were stirred
either at room temperature or at 70 C.
To assess the degree of CIPRO incorporation, the samples
were centrifuged, and the sediment was washed from excess of
the drug either through re-dispersion in acidic solution of pH¼
2.0 (batches A and B) or in pure deionized water (batch C). The
CPFh samples were centrifuged again, and subsequently the
supernatant was collected and analysed with UV-VIS spectros-
copy using an Agilent 8453 spectrophotometer in a wavelength26538 | RSC Adv., 2017, 7, 26537–26545interval ranging from 200 to 400 nm. This process was repeated
5 times, which proved to be suﬃcient to reach a stable and
minimal CIPRO concentration released into the supernatant,
indicating that the remaining drug was adsorbed, either
successfully intercalated into the Fh clay particles or attached to
its outer particle surfaces.
Aer washing, the stable sediment was dried at room
temperature and analysed with X-rays using the I911-SAXS
beamline33 at the MAX-lab Synchrotron Facility in Lund, Swe-
den. We used a wavelength l ¼ 0.091 nm covering a scattering
vector, Q, in the range from about 1 to 7 nm1 (corresponding to
scattering angles in the range 2q z 0.85 to 2q z 5.85). In
order to verify the diﬀusion rate of the incorporation process,
samples were thus collected at several intervals aer the initial
drug exposure, respectively at 5 hours, 24 hours, 5 days and 13
days.
CIPRO-release from the CPFh composite at pH 1.5 as
a function of time and temperature, analysed with UV-VIS
spectroscopy
Release studies were conducted in a SGA solution, which was
prepared by adding 2.00 g of NaCl to 1.000 L of deionized water
adjusted to pH ¼ 1.5 by adding HCl. For the release experi-
ments, 25 mg of washed and dried CPFh from batch B were
added to 50 mL of the SGA solution at 24 C, 37 C, 55 C and
70 C, and stirred. At certain times, the solutions were centri-
fuged, and aliquots of 0.25 mL were extracted from the super-
natant for analysis. The solutions were re-stirred between each
centrifugation and extraction.
Minimal inhibitory concentration (MIC) and minimal
bactericidal concentration (MBC) determination
Standard MIC and MBC assays were done by the micro dilution
method essentially as described in standard protocols34 in order
to determine the eﬃciency of the clay–drug complex against
Gram-negative (Escherichia coli ATCC® 25922™; Pseudomonas
aeruginosa ATCC® 27853™; Acinetobacter baumannii ATCC®
19606™; Klebsiella pneumoniae® 700603™) and Gram-positive
(Staphylococcus aureus ATCC® 29213™; Enterococcus faecalis
ATCC® 29212™) human pathogens. The same was done for
pure CIPRO and LiFh.
The diluted bacterial cultures for the MIC and MBC deter-
mination were prepared by growing the cultures to OD600 $ 0.1
in 10 mL of cation adjusted Mueller–Hinton broth (pH 7.3;
CAMHB). Cultures were diluted in CAMHB so that the nal
concentration was 5  105 bacteria per mL during the MIC test.
Compounds for antimicrobial activity testing were added as
a twofold dilution series.
MBC were determined by plating 100 ml of cells from the 1 
MIC, 2  MIC and 4  MIC wells on non-selective LB-agar
plates. The MBC was dened as the compound concentration
that killed 99.9% of the start inoculum.
Toxicity determination
Human Jurkat cells (ATCC) were maintained in Dulbecco's
Modied Eagle medium (Gibco) supplemented with 10% fetal-This journal is © The Royal Society of Chemistry 2017
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View Article Onlinecalf serum (Invitrogen), and 2 mM glutamine (Sigma-Aldrich) at
37 C in a humidied atmosphere containing 5% CO2. For cell
viability assays the cells were seeded in CELLine bioreactor
asks (Sigma-Aldrich). Aer 48 h cell viability was determined
by counting cells stained with Trypan Blue (Sigma-Aldrich) at
a nal concentration of 0.2%.Results and discussion
CIPRO intercalation
XRD patterns obtained for the CPFh powders, batch A, are shown
in Fig. 1. The 001 and 002 Bragg reections correspond to an
interlayer periodicity of 2.2 nm. This is markedly larger than the
interlayer periodicity of the native LiFh, which in the mono-
hydrated state is 1.2 nm. Such interlayer expansion is a clear
indication of the successful intercalation of CIPRO into the clay
interlayers. Under acidic conditions no signicant diﬀerences
between samples prepared at ambient or elevated temperatures
were observed (inset of Fig. 1). Because we do not observe
signicant changes in diﬀraction proles from samples extracted
aer 5 hours (CPFh – 5 hours) and 13 days (CPFh – 13 days), it
appears that the intercalation process is completed in less than
a day. Under acidic condition, because of the loss of crystallinity
of the intercalated drug,35 the Bragg reections of pure CIPRO are
absent in the CPFh diﬀraction patterns. Samples prepared at
pure deionized water, batch C, show a more complex scattering
prole, as depicted in Fig. 2, which is in full agreement with the
previous studies on CIPRO intercalated into Fh.13
The results obtained from the batch C can be understood as
follows. At room temperature, when the clay particles areFig. 1 Powder X-ray diﬀraction patterns from monohydrated LiFh, CIPR
batch A. The CPFh XDR patterns presented in this ﬁgure are from samples
mixing. The inset presents the XRD patterns for samples prepared at ro
extracted after 13 days of mixing.
This journal is © The Royal Society of Chemistry 2017dispersed into deionized water, the pH of the solution is driven
towards around 9.36 However, the charge of the CIPRO mole-
cules is pH-dependent, with an acid dissociation constant pKa2
¼ 8.7.28,37 Thus, in such conditions, the CIPRO molecules might
be either in the anionic or neutral forms, and may not inter-
calate easily. On heating, a very convoluted variation of CIPRO's
net charge occurs, most likely due to a diﬀerent degree of drug
intercalation, that gives rise to a more convoluted X-ray pattern
(inset of Fig. 2), that could partially be linked to the temperature
dependence of the pH.
For the samples prepared under controlled pH, batches A
and B, UV-VIS spectroscopy shows that aer 24 h of mixing
stable CIPRO concentrations are reached, which were
measured to be respectively 0.25 0.01 g and 0.49  0.01 g per
1.00 g of LiFh. Although for the batch A all the added CIPRO
was retained in the resulting CPFh composite, this is not the
optimal situation as the estimated saturation amount is 0.53 g
of CIPRO per 1.00 g of LiFh. Therefore, for this batch, not all
cations were exchanged by the drug molecules. On the other
hand, for batch B the amount of drug retained is not only close
to the calculated saturation amount but higher than the
amount of CIPRO adsorbed to Fh without pH control (0.350
gCIPRO gHost
1).13 This value is also considerably higher than
what is adsorbed by other host systems, such as rectorite:
0.135 gCIPRO gHost
1;23 montmorillonite: 0.395 gCIPRO gHost
1;23
oxidized xerogel: 0.060 gCIPRO gHost
1;38 chemically prepared
carbon (wet): 0.133 gCIPRO gHost
1;39 vermiculite modied with
amphoteric surfactant of phosphatidylcholine: 0.094 gCIPRO
gHost
1.40 Based on these results drug release analysis was
performed on batch B only.O and CPFh prepared at room temperature in acid solution (pH ¼ 2),
extracted after 5 hours (CPFh– 5 hours) and 13 days (CPFh– 13 days) of
om temperature (CPFh – 24 C) and at 70 C (CPFh – 70 C), both
RSC Adv., 2017, 7, 26537–26545 | 26539
Fig. 2 Powder X-ray diﬀraction patterns from monohydrated LiFh, CIPRO and CPFh prepared at room temperature in deionized water with no
pH control, batch C. The CPFh XDR patterns presented in this ﬁgure are from samples extracted after 5 hours (CPFh – 5 hours) and 13 days (CPFh
– 13 days) of mixing. The inset presents the XRD patterns for samples prepared at room temperature (CPFh – 24 C) and at 70 C (CPFh – 70 C),
both extracted after 13 days of mixing.
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View Article OnlineCIPRO release
Release studies from samples from the batch B were conducted
in SGA at room temperature (24 1 C), body temperature (37
2 C) and at 55  2 C and 70  3 C. CIPRO release is gradual
and temperature dependent, with higher temperatures favour-
ing a faster release (Fig. 3). The release prole shows a plateau
in roughly 50 hours at 70 C, 165 hours at 55 C and 37 C, and
aer more than 200 hours at 24 C.
A series of factors can inuence the drug release from a given
system resulting in diﬀerent release rates,1,41–43 such as
temperature, the host shape and porosity as well as solubility
and diﬀusivity of the drug molecule itself. Over the years, a wide
number of models have been derived from the Fick's diﬀusion
law and proposed to explain drug release.41–43 Here we applied
the semi empirical Korsmeyer–Peppas model44,45 to describe the
CIPRO's release from LiFh. This is a power law which relates the
fraction of drug released (ft) to time (t) and is used to t data
within 60% of the fraction of drug released as follows:
ft ¼ kKPtn (1)
where, n and kKP are respectively the release exponent and
constant, which are related to the release mechanism and to the
physical and geometric characteristics of the drug delivery
system. In the case of a slab geometry, n ¼ 0.5 characterizes
a release driven by Fickian diﬀusion, for 0.5 < n < 1 the release is
characterized by anomalous diﬀusion, and nally, for n¼ 1, the
diﬀusion is non-Fickian and the release rate is time-indepen-
dent.44,45 The latter is especially appropriate for medical26540 | RSC Adv., 2017, 7, 26537–26545treatments that demand a stable level of the drug into the
organism, such as antibiotics.42
If in a particular temperature range, the drug release is
mostly thermally activated, all other factors inuencing the
release can be neglected, i.e. host geometry, solubility and
diﬀusivity of the drug molecule itself as well as concentration of
incorporated drug. Therefore, the release rate can be described
by the Arrhenius equation
k ¼ AeEa=RT (2)
where A is the pre-exponential factor, T the temperature in
Kelvin, R the gas constant and Ea the average activation energy.
Then if we dene that kKP is related to k by a power law, with n as
exponent, eqn (1) becomes
ft ¼ kntn (3)
Taking the logarithm in both sides of eqn (3) and reorgan-
izing the terms, we get
ln(ft) ¼ n ln(k) + n ln(t) (4)
According to eqn (4), if the assumption that the CIPRO's
release is mostly thermally activated, by plotting ln(ft) versus
ln(t) a straight line would be obtained and its slope would be
numerically equal to the release exponent. Such plot presented
as inset in Fig. 3, shows that indeed a straight line can be tted
at least in the rst 20 hours of the drug release process, (ln(20)
y 3). The tting results are summarized in Table 1, where one
see that n becomes larger than 0.5 as the temperatureThis journal is © The Royal Society of Chemistry 2017
Fig. 3 Normalized release proﬁle of CIPRO from solutions of batch B in synthetic gastric acid at four diﬀerent temperatures. Arrows indicate the
temperature at which each set of data was collected and the dashed lines are guide lines to facilitate the viewing. The maximal release
concentration of 5.3 mg is achieved after roughly 50 hours at 70  3 C and after more than 200 hours at 24  1 C. The resulting continuous
lines shown in the inset – log–log plot of the data ﬁtted using eqn (4) – indicate that in the ﬁrst 20 hours the CIPRO release is mostly thermally
activated.
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View Article Onlineapproaches body temperature, indicating an anomalous drug
diﬀusion from the clay particles.45
The average activation energy Ea, for the CIPRO's release can
be calculated from the slope of the straight line obtained by
plotting ln(k) versus 1/T (Arrhenius plot), as depicted in Fig. 4a.
According to that, Ea is numerically equal to the slope times the
gas constant R, resulting in 22.0  0.5 kJ mol1 and indicating
that the release process is diﬀusion-controlled.46
In order to further verify our assumption that the CIPRO's
release is mostly a thermally activated process and thereby
conrm the accuracy of the activation energy found from the
Arrhenius plot (Fig. 4a), eqn (2) was replaced into eqn (4) giving:
lnðftÞ
n
 lnðtÞ ¼ lnðAÞ  Ea
RT
(5)
where Ea is the instantaneous activation energy at the time t. If
a process is exclusively thermally activated, using this approach
the data points obtained for each temperature at diﬀerentTable 1 Release exponent n and release constant k obtained from the
ﬁtting of the Korsmeyer–Peppas model to the release proﬁle curves of
CPFh samples (batch B) obtained at diﬀerent temperatures
Temperature n k (h1)
24 C 0.85  0.07 0.009  0.004
37 C 0.81  0.06 0.024  0.008
55 C 0.59  0.09 0.019  0.007
70 C 0.34  0.06 0.037  0.009
This journal is © The Royal Society of Chemistry 2017experimental times will collapse to the same point and a master
curve obtained if all the temperatures are considered.
Fig. 4b shows the plot of the le hand of eqn (5) versus 1000/T
for the 20 rst hours of CIPRO release, when the Arrhenius
behaviour is valid (linear dependence shown in the inset of
Fig. 3). The dispersion between the points for diﬀerent times is
larger at 70 C (at 70 C, 1000/Tz 2.91), indicating that in this
temperature other factors are inuencing CIPRO release, as for
example possibly changes in the aspect ratio of the clay particles
due to delamination.32 On the other hand, at body temperature,
with exception of the data collected aer 8 hours of release, the
collapsing is almost perfect. This is yet another clear indication
that at this temperature the release is mostly thermally acti-
vated. From the slopes of each curve at Fig. 4b, an instanta-
neous activation energy was obtained. These values conrm the
average activation energy of 22 kJ mol1 as depicted in Fig. 4c.
As the activation energy obtained in this work is three times
lower than the value previously reported for the CPFh system
prepared without pH control (67 kJ mol1; pH around 8),13 our
results show that the release of CIPRO from samples prepared
at acidic pH is facilitated. Indeed a faster CIPRO's release at
37 C in synthetic gastric acid (around 80% of the drug is release
aer 50 hours, Fig. 3) is observed when comparing the release
data from samples prepared without pH control (around 35% of
the drug is release aer 50 hours (ref. 13)). These diﬀerences
together with the dissimilarity in the amount of CIPRO captured
by Fh with and without pH control, 0.49 gCIPRO ghost
1 (this
work) and 0.35 gCIPRO ghost
1,13 further conrm that for samplesRSC Adv., 2017, 7, 26537–26545 | 26541
Fig. 4 (a) Arrhenius plot used to obtain the average activation energy as described in eqn (2), (b) master curve obtained using eqn (5) to further
verify if the drug release is mostly thermally activated for the ﬁrst 20 hours and (c) comparison between the average activation energy obtained
using the Arrhenius plot (straight line) and the instantaneous activation energy using eqn (5) (dots).
Fig. 5 Human Jurkat cells viability in tissue culture after 48 hours in
the presence of CIPRO and CPFh.
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View Article Onlineprepared at pH ¼ 2 the interactions between the drug and the
clay are weaker.47
Moreover, the activation energy reported in this work for the
CIPRO release is close to the value reported for the adsorption of
this drug via cation exchange onto a carbon matrix chemically
prepared from palm leaets39 (17 kJ mol1) and to the activation
energy found by Crosson et. al. for the sorption of denatonium
onto the synthetic smectite montmorillonite (25.9 kJ mol1).48
Furthermore, the obtained Ea value is within the range of ion
exchange in mesoporous and macro porous materials (24–40 kJ
mol1).49 Together these ndings support the idea that the
CIPRO's release is governed by cation exchange.
Toxicity and antibacterial tests
The toxicity of CPFh was determined by analyzing the viability of
human Jurkat cells in tissue culture aer 48 hours in the presence
of the clay-drug complex and comparing with the toxicity of the
pure drug. Fig. 5 shows the results for both CIPRO and CPFh. In
both cases, only at high concentrations we observe a slight
reduction in cell viability. Hence, at 0.1 mg mL1 approximately
90% of the cells were viable, showing that the clay–drug complex,
CPFh, preserve the same toxicity as the pure CIPRO.
The minimum inhibitory and bactericidal concentrations of
CIPRO and CPFh, together with the minimum inhibitory
concentration of LiFh for E. coli, P. aeruginosa, A. baumannii, K.
pneumoniae, S. aureus and E. faecalis are presented in Table 2.
One may notice that LiFh showed no antimicrobial activity
towards any of these pathogens in contrast to CIPRO and CPFh
that are eﬀective against the same bacteria. With exception of P.
aeruginosa, MIC ¼ MBC for both the pure drug and the clay-26542 | RSC Adv., 2017, 7, 26537–26545drug complex, which is an expected result given the mode of
action of CIPRO.50 Comparing the antibactericidal eﬃcacy of
CPFh with the pure CIPRO we notice that the concentration of
CPFh needed to inhibit bacterial growth is two to four times
higher than the pure drug. This does however not indicate
a reduced activity of the clay–drug complex relative to that of the
pure drug: the UV-VIS results demonstrate that 1.49 g of CPFhThis journal is © The Royal Society of Chemistry 2017
Table 2 MIC and MBC of CIPRO, CPFh and LiFh for E. coli, P. aeruginosa, A. baumannii, K. pneumoniae, S. aureus and E. faecalis
CIPRO MIC
(mg mL1)
CIPRO MBC
(mg mL1)
CPFh MIC
(mg mL1)
CPFh MBC
(mg mL1)
Li MIC
(mg mL1)
E. coli ATCC 25922 0.015 0.015 0.06 0.06 >128
P. aeruginosa ATCC 27853 0.25 1.00 1.00 2.00 >128
A. baumannii ATCC 19606 1.00 1.00 2.00 2.00 >128
K. pneumoniae ATCC 700603 0.50 0.50 2.00 2.00 >128
S. aureus ATCC 29213 0.50 0.50 2.00 2.00 >128
E. faecalis ATCC 29212 2.00 2.00 8.00 8.00 >128
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View Article Onlinecontains up to 0.49 g of CIPRO, meaning that about 33% of
CPFh is composed of cipro while the remaining 67% is the
carrier. Taking this into account, we conclude that the anti-
bacterial eﬃcacy of CPFh is similar to that of pure CIPRO.Conclusions
We demonstrated that the antibiotic ciprooxacin (CIPRO) can
be intercalated into the interlayers of the synthetic clay mineral,
uorohectorite (Fh), likely replacing the native Li-cations to
produce the clay–drug composite CPFh under diﬀerent pHs.
The intercalation is veried experimentally using X-ray powder
diﬀraction (XRD) and UV-VIS spectroscopy. Under acidic
conditions, Fh have retained at least 25% more CIPRO than
other hosts systems reported in the literature, being very close
to the theoretical prediction. On the other hand, samples
prepared without pH control show a more complex XRD prole
and a lower degree of drug intercalation.
In synthetic gastric acid at temperatures ranging between
24 C and 70 C, UV-VIS spectroscopy measurements show that
the release proles of CIPRO from CPFh are strongly tempera-
ture dependent. By tting the release prole curves of CPFh
using the semi-empirical Korsmeyer–Peppas model we show
that the drug release is mostly thermally activated in the rst 20
hours. In addition, at body temperature the release exponent (n
¼ 0.81  0.06), which is related to the release mechanism
follows in the range characterizing anomalous diﬀusion, 0.5 < n
< 1. Using the Arrhenius equation an activation energy of 22.0
0.5 kJmol1 was obtained, indicating that the CIPRO's release is
a diﬀusion-controlled process. This result diﬀers from the value
obtained previously, where the higher activation energy indi-
cates that, for samples prepared without pH control, the release
is chemically controlled. Furthermore, these diﬀerences in the
activation energy, together with the contrasts in the amount of
drug captured, indicates that in the case of the samples
prepared at pH ¼ 2 the interactions between the drug and the
clay particles are weaker. In addition, the higher drug adsorp-
tion at acidic pH, where CIPRO is negatively charged, together
with the similarities in the activation energy reported in the
literature for other cation exchange processes, suggest that the
CIPRO capture at acidic pHs occurs via cation exchange.
Antibacterial susceptibility testing demonstrated that the
activity of CPFh against E. coli, P. aeruginosa, A. baumannii, K.
pneumoniae, S. aureus and E. faecalis was similar to that of pure
CIPRO. Along with the observation that the toxicity of the clay–This journal is © The Royal Society of Chemistry 2017drug complex was low and also similar to that of CIPRO alone,
we provide strong evidence that LiFh is a carrier that promotes
drug release in a slow and controlled manner without inter-
fering with the drug's action and without causing adverse
eﬀects on human cells.
In order to further verify the importance of pH, and conse-
quently the electric charge of CIPRO in the drug delivery process,
release studies conducted in basic solutions, obtained for
example by adding NaOH to deionized water, are of great interest.
In this case, CIPRO should be negatively charged, which could
promote its rapid release its replacement by Na+. Therefore, it can
be expected that the X-ray scattering prole from the same batch
but prepared by adding CPFh to basic NaOH solutions would
display a pattern associated with sodium uorohectorite (NaFh).
To conclude, the high drug adsorption capacity as well as the
slow and gradual release reported in this work adds the
synthetic smectite uorohectorite as a promising material
within the clay family.Acknowledgements
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